Center-Authored Papers

Filters: Author is Wundes, Annette  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
United States Food and Drug Administration
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
United States
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Treatment Outcome
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Transplantation, Autologous
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Stroke Volume
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Shared Resources
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Safety
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Retrospective Studies
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Research Trials Office Core Facility - Biostatistics Service
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
RECURRENCE
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Patient Dropouts
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Patient Compliance
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Multiple Sclerosis, Relapsing-Remitting
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Multiple Sclerosis
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
MITOXANTRONE
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Middle Aged
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Male
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Magnetic Resonance Imaging
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Injections, Intravenous
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract
Immunosuppressive Agents
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Humans
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA.  2010.  Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.. Clinical neurology and neurosurgery. 112(10):876-82. Abstract